Navigation Links
RNA build-up linked to dementia and motor neuron disease
Date:10/30/2013

A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica.

Frontotemporal dementia and motor neuron disease are related neurodegenerative diseases that affect approximately 15,000 people in the UK. Frontotemporal dementia causes profound personality and behaviour changes. Motor neuron disease leads to muscle weakness and eventual paralysis.

The most common known cause for both frontotemporal dementia and motor neuron disease is an unusual genetic mutation in the C9orf72 gene. The mutation involves a small string of DNA letters at the beginning of the gene, which expand massively to produce thousands of copies.

The new research, funded by Alzheimer's Research UK and the Medical Research Council, has shown that this DNA expansion acts in a peculiar way, leading to the generation of unexpected RNA molecules that could cause the disease.

When a gene is turned on, an RNA copy of the gene's DNA is generated. The gene's DNA code has directionality, so that it is normally turned on in only one direction, termed the 'sense direction'. The new research shows that the DNA expansion is turned on in both directions.

This leads to the normal sense RNA being produced, as well as RNA in the opposite direction, termed 'antisense RNA'. Both RNA types accumulate into aggregates in the neurons of people with frontotemporal dementia.

Intriguingly, the research showed that people with more of these aggregates in their brains developed the disease earlier than people with less RNA aggregates. This correlation suggests that the build-up may be important in causing frontotemporal dementia and motor neuron disease, making the C9orf72 DNA expansion a potential target for therapy.

Dr Adrian Isaacs, lead researcher at the UCL Institute of Neurology, said: ""These findings identify new, potentially toxic molecules in diseases caused by DNA expansions. The next steps will be to determine how they might kill neurons and how to stop them building up."

Dr Simon Ridley, Head of Research at Alzheimer's Research UK, the UK's leading dementia research charity, said: "The discovery of the C9ORF72 gene was a major step forward for research into frontotemporal dementia and motor neuron disease, and it's positive to see researchers beginning to untangle how this gene may cause these diseases in some people.

"Alzheimer's Research UK is delighted to have supported this promising study. By unravelling some of the biological mechanisms at play, this research could take us further on the road to new treatments that are so desperately needed by the thousands of people with these devastating diseases. For these results to reach their full potential it's vital that we continue to invest in research."


'/>"/>

Contact: David Weston
d.weston@ucl.ac.uk
44-203-108-3844
University College London
Source:Eurekalert

Related medicine news :

1. Cancer drug prevents build-up of toxic brain protein
2. Protein build-up leads to neurons misfiring
3. Weight at time of diagnosis linked to prostate cancer mortality
4. Male birth defect is weakly linked to pesticide exposure, Stanford-led study finds
5. Poor motor performance linked to poor academic skills in the first school years
6. Early skin-to-skin contact linked to higher breastfeeding rates
7. Headaches in lupus patients not linked to disease activity study says
8. Prevalence of household gun ownership linked to child gun shot wounds
9. Casey Gollan: A Step-by-Step Guide to Creating a LinkedIn Account
10. High blood sugar levels linked to increased wound complications after surgery
11. Abuse, lack of parental warmth in childhood linked to multiple health risks in adulthood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: